

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

Py8119

RRID:CVCL_AQ09

Type: Cell Line

Proper Citation

RRID:CVCL_AQ09

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_AQ09

Proper Citation: RRID:CVCL_AQ09

Description: Cell line Py8119 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Defining Citation: [PMID:22531600](#), [PMID:24368187](#)

Comments: Miscellaneous: STR profile from personal communication of Rodriguez-Tarduchy Segovia, Gemma.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: Py8119

Synonyms: PY8119

Cross References: ATCC:CRL-3278, Wikidata:Q54948762

ID: CVCL_AQ09

Record Creation Time: 20220427T221446+0000

Record Last Update: 20260904T015501+0000

Ratings and Alerts

No rating or validation information has been found for Py8119.

No alerts have been found for Py8119.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Murrey MW, et al. (2026) The myeloid SRC family kinase HCK regulates breast cancer growth by activating tumor-associated macrophage-led invasion and inhibiting cytotoxic T cell activity. *Frontiers in immunology*, 17, 1709102.

Fan G, et al. (2026) Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways. *Cancer cell*, 44(6), 1160.

Zhou T, et al. (2026) Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(40), e21541.

Wang X, et al. (2026) Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. *Cancer cell*, 44(3), 658.

Hayward MK, et al. (2026) Tissue tension fosters macrophage-driven lipid peroxidation-induced DNA damage. *Cancer cell*, 44(6), 1255.

Hsu L, et al. (2025) Secreted frizzled-related protein 2 monoclonal antibody-mediated IFN- γ reprograms tumor-associated macrophages to suppress triple negative breast cancer. *Breast cancer research : BCR*, 27(1), 209.

Han Y, et al. (2025) Niche Macrophages Recycle Iron to Tumor Cells and Foster Erythroblast Mimicry to Promote Bone Metastasis and Anemia. *bioRxiv : the preprint server for biology*.

Beeghly GF, et al. (2025) Large adipocytes alter mode of lipid release and promote breast cancer malignancy. *bioRxiv : the preprint server for biology*.

Han Y, et al. (2025) Tumors hijack macrophages for iron supply to promote bone metastasis and anemia. *Cell*.

Zhu L, et al. (2025) Synergistic Promotion of Triple-Negative Breast Cancer Tumorigenesis and Metastasis by Oral Polystyrene Nanoplastics Exposure via Alloprenovotella-Derived Glutamate and Platelet Activation. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(46), e08310.

Nishida-Aoki N, et al. (2025) Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. *Cell reports. Medicine*, 102357.

Tailor D, et al. (2025) Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer. *Cell reports. Medicine*, 6(11), 102451.

Pitter MR, et al. (2024) PAD4 controls tumor immunity via restraining the MHC class II machinery in macrophages. *Cell reports*, 43(3), 113942.

Zhao L, et al. (2024) IL-17A/CEBP β /OPN/LYVE-1 axis inhibits anti-tumor immunity by promoting tumor-associated tissue-resident macrophages. *Cell reports*, 43(12), 115039.

Cheng X, et al. (2024) Loss of ZNF408 attenuates STING-mediated immune surveillance in breast carcinogenesis. *iScience*, 27(7), 110276.

Riquelme MA, et al. (2024) Antibody-activation of connexin hemichannels in bone osteocytes with ATP release suppresses breast cancer and osteosarcoma malignancy. *Cell reports*, 43(7), 114377.

Zhou T, et al. (2024) PGRN inhibits CD8⁺T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM. *Cancer immunology, immunotherapy : CII*, 73(5), 76.

Xu G, et al. (2024) Proteomic Profiling of Serum Extracellular Vesicles Identifies Diagnostic Signatures and Therapeutic Targets in Breast Cancer. *Cancer research*, 84(19), 3267.

Kim H, et al. (2023) Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. *Cell reports*, 42(10), 113256.

Roche ME, et al. (2023) TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NF κ B activation in breast cancer. *International journal of cancer*, 153(9), 1671.